SHAREHOLDERS' EQUITY | 6. SHAREHOLDERS’ EQUITY Stock-based compensation As of June 30, 2023, the Company had 3,810,000 issued and outstanding stock options that were issued under the 10% Rolling Stock Option Plan, as amended and restated (the “2011 Plan”) and 1,270,000 issued and outstanding stock options that were issued under its 2022 Equity Incentive Plan (the “2022 Plan”). The 2011 Plan was replaced in 2022 by the 2022 Plan, and as such, no additional stock options can be granted under the 2011 Plan. Under the 2011 Plan, our Board of Directors could from time-to-time grant stock options to eligible directors, officers, employees, and consultants. The maximum term of any stock option grant under the 2011 Plan was 10 years. Under the 2022 Plan, as approved by our shareholders at the annual meeting of shareholders on August 23, 2022, our Board of Directors is authorized to grant stock options, stock appreciation rights, restricted stock units, performance stock units and other cash and share-based awards to eligible directors, officers, employees, or consultants up to a maximum of 17,236,689 common shares. The maximum term of any grant under the 2022 Plan is 10 years. The Company estimates the fair value of its stock option grants using the Black-Scholes option valuation model and the closing price of our common shares on the business day prior to the grant date. The significant assumptions used to estimate the fair value of the 1,020,000 and 1,830,000 stock options awards granted during the six months ended June 30, 2023 and 2022, respectively, were as follows: Six Months Ended June 30, 2023 2022 Risk-free interest rate 1.54 % 1.71 % Expected volatility 123 % 135-144 % Expected dividend yield Nil Nil Expected term in years 8 8 The following table summarizes our stock option activity for each of the six months ended June 30, 2023 and 2022: Six Months Ended June 30, 2023 2022 Weighted Weighted Average Average Number of Stock Exercise Number of Stock Exercise Options Price Options Price Outstanding, beginning of period 4,160,000 $ 1.26 2,180,000 $ 1.18 Granted 1,020,000 $ 0.38 1,830,000 $ 1.40 Exercised (100,000) $ 0.07 — $ — Outstanding, end of period 5,080,000 $ 1.10 4,010,000 $ 1.28 Exercisable, end of period 3,726,250 $ 1.34 1,752,500 $ 0.92 Non-vested, end of period 1,353,750 $ 0.44 2,257,500 $ 1.56 The following table summarizes the intrinsic value and weighted average remaining life for stock options as of June 30, 2023: Weighted Average Remaining As of June 30, 2023: Intrinsic Value Life (Years) Stock options outstanding $ 110 7.0 Stock options exercisable $ 110 6.2 Stock options non-vested $ — 9.4 Stock-based compensation expense is included in corporate administration expenses within the Company’s interim condensed consolidated statements of operations. For the three months ended June 30, 2023 and 2022, the Company recognized compensation expense related to stock option awards of $159 and $1,033, respectively. For the six months ended June 30, 2023 and 2022, the Company recognized compensation expense related to stock option awards of $331 and $2,028, respectively. As of June 30, 2023, there was approximately $198 of total unrecognized compensation cost related to the 1,353,750 unvested stock options that is expected to be recognized over a weighted-average remaining vesting period of approximately one The weighted-average grant-date fair value of options granted during the six months ended June 30, 2023 was $0.35. |